Fluparoxan, formerly known as GR-50360; GR-50360A, is a potent α2-adrenergic receptor antagonist (pKB = 7.9) with excellent α2/α1 selectivity (2630 fold). It was shown to possess central α2-adrenoceptor antagonist activity after orally bioavailable doses in man and was patented as an antidepressant by Glaxo in the early 1980s, but its development was discontinued when the compound failed to show a clear clinical advantage over existing therapies. References: Borthwick AD. Fluparoxan: A Comprehensive Review of its Discovery, Adrenergic and CNS activity and treatment of Cognitive Dysfunction in central Neurodegenerative diseases. Mini Rev Med Chem. 2016 Mar 21. [Epub ahead of print] PubMed PMID: 26996616.

纯度：≥98%

CAS：105226-30-0